Lantheus Holdings, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Lantheus Holdings, Inc. (LNTH) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $1.19 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2025-02-26
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-12-31 was $1.29M.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-06-30 was -$100.00K, a 101.32% decline year-over-year.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $1.19M, a 87.13% decline from fiscal 2023.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $9.28M.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was -$25.40M.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was -$70.40M, a 8900.00% decline from fiscal 2020.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.29M derived: sum of 2 quarters · filed 2025-02-26 | $1.19M derived: sum of 3 quarters · filed 2025-02-26 | $1.19M 10-K · filed 2025-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$100.00K derived: sum of 2 quarters · filed 2024-11-06 | -$100.00K 10-Q · filed 2024-11-06 | -$300.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2024-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$100.00K 10-Q · filed 2024-07-31 | -$300.00K derived: sum of 3 quarters · filed 2025-02-26 | $200.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | -$200.00K derived: sum of 2 quarters · filed 2025-02-26 | $300.00K derived: sum of 3 quarters · filed 2025-02-26 | $7.88M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $300.00K derived: sum of 2 quarters · filed 2025-02-26 | $7.88M derived: sum of 3 quarters · filed 2025-02-26 | $9.28M 10-K · filed 2025-02-26 |
| 2023-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $8.07M derived: sum of 2 quarters · filed 2024-11-06 | $9.47M 10-Q · filed 2024-11-06 | $8.38M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $7.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $8.97M 10-Q · filed 2024-07-31 | $7.88M derived: sum of 3 quarters · filed 2024-07-31 | $8.88M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | $1.40M 10-Q · filed 2024-05-02 | $300.00K derived: sum of 2 quarters · filed 2024-05-02 | $1.30M derived: sum of 3 quarters · filed 2024-05-02 | -$6.00M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$100.00K derived: sum of 2 quarters · filed 2024-02-22 | -$7.40M derived: sum of 3 quarters · filed 2024-02-22 | -$25.40M 10-K · filed 2024-02-22 |
| 2022-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$6.30M derived: sum of 2 quarters · filed 2023-11-02 | -$24.30M 10-Q · filed 2023-11-02 | -$63.70M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$7.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$25.30M 10-Q · filed 2023-08-03 | -$64.70M derived: sum of 3 quarters · filed 2023-08-03 | -$67.70M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$18.00M 10-Q · filed 2023-05-04 | -$57.40M derived: sum of 2 quarters · filed 2023-05-04 | -$60.40M derived: sum of 3 quarters · filed 2023-05-04 | -$87.20M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$39.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$42.40M derived: sum of 2 quarters · filed 2023-02-23 | -$69.20M derived: sum of 3 quarters · filed 2023-02-23 | -$70.40M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$29.80M derived: sum of 2 quarters · filed 2022-11-03 | -$31.00M 10-Q · filed 2022-11-03 | -$29.30M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$26.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$28.00M 10-Q · filed 2022-08-04 | -$26.30M derived: sum of 3 quarters · filed 2022-08-04 | -$27.20M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$1.20M 10-Q · filed 2022-04-29 | $500.00K derived: sum of 2 quarters · filed 2022-04-29 | -$400.00K derived: sum of 3 quarters · filed 2022-04-29 | |
| 2020-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $800.00K derived: sum of 2 quarters · filed 2022-02-24 | $800.00K 10-K · filed 2022-02-24 | |
| 2020-09-30 | -$900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$900.00K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |